{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T11:14:26Z","timestamp":1771931666973,"version":"3.50.1"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) have demonstrated substantial clinical benefit across a wide range of malignancies. With their expanding use, uncommon immune-related events, including hematologic abnormalities and lymphoid proliferations, are increasingly recognized. However, a causal relationship between ICI exposure and lymphoma development remains unproven.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case description<\/jats:title>\n                    <jats:p>We report a 70-year-old woman with moderately to poorly differentiated gastric adenocarcinoma who was diagnosed with diffuse large B-cell lymphoma (DLBCL) during postoperative treatment with FOLFOX chemotherapy combined with the PD-1 inhibitor sintilimab. During therapy, the patient developed recurrent pleural and pericardial effusions. Early pleural fluid cytology revealed atypical lymphoid cells with occasional Epstein\u2013Barr virus\u2013encoded RNA (EBER) positivity, but immunophenotypic and clonality assessments were not performed, precluding a definitive lymphoma diagnosis at that time. Subsequent cytological, immunophenotypic, and molecular studies confirmed Ann Arbor stage IV DLBCL, predominantly presenting as malignant effusions. The patient achieved remission with R-CHOP therapy but later experienced relapsed and refractory disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case illustrates a temporal association between PD-1 inhibitor\u2013based therapy and the diagnosis of DLBCL. Given the lack of baseline systemic staging, overlapping PET\/CT findings, early diagnostic uncertainty in effusion cytology, and potential contributions from chemotherapy-induced immune perturbation and EBV-associated processes, a direct causal relationship cannot be established. This report underscores the importance of comprehensive baseline evaluation and cautious interpretation of atypical lymphoid findings during immunotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1763711","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T07:14:59Z","timestamp":1770880499000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Temporal association of diffuse large B-cell lymphoma with PD-1 inhibitor therapy in a patient with gastric adenocarcinoma: a case report"],"prefix":"10.3389","volume":"17","author":[{"given":"Yiqing","family":"Jiang","sequence":"first","affiliation":[{"name":"Weifang People\u2019s Hospital, Shandong Second Medical University","place":["Weifang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun","family":"Wu","sequence":"additional","affiliation":[{"name":"Weifang People\u2019s Hospital, Shandong Second Medical University","place":["Weifang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Hu","sequence":"additional","affiliation":[{"name":"Weifang People\u2019s Hospital, Shandong Second Medical University","place":["Weifang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingxin","family":"Yu","sequence":"additional","affiliation":[{"name":"Weifang People\u2019s Hospital, Shandong Second Medical University","place":["Weifang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhang","family":"Xu","sequence":"additional","affiliation":[{"name":"Weifang People\u2019s Hospital, Shandong Second Medical University","place":["Weifang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zihan","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Sunshine Fusion Hospital","place":["Weifang, Shandong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongxuan","family":"Cao","sequence":"additional","affiliation":[{"name":"Hematology of the First Affiliated Hospital, WeiFang People\u2019s Hospital, Shandong Second Medical University","place":["Weifang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Weifang People\u2019s Hospital, Shandong Second Medical University","place":["Weifang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanfang","family":"Gao","sequence":"additional","affiliation":[{"name":"Weifang People\u2019s Hospital, Shandong Second Medical University","place":["Weifang, China"]},{"name":"Oncology Laboratory of the First Affiliated Hospital, WeiFang People\u2019s Hospital, Shandong Second Medical University","place":["Weifang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuzhen","family":"Liu","sequence":"additional","affiliation":[{"name":"Weifang People\u2019s Hospital, Shandong Second Medical University","place":["Weifang, China"]},{"name":"Oncology Laboratory of the First Affiliated Hospital, WeiFang People\u2019s Hospital, Shandong Second Medical University","place":["Weifang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanhong","family":"Ding","sequence":"additional","affiliation":[{"name":"Weifang People\u2019s Hospital, Shandong Second Medical University","place":["Weifang, China"]},{"name":"Oncology Laboratory of the First Affiliated Hospital, WeiFang People\u2019s Hospital, Shandong Second Medical University","place":["Weifang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.964442","article-title":"The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers","volume":"13","author":"Tang","year":"2022","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery technologies for cancer immunotherapy","volume":"18","author":"Riley","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17091408","article-title":"Advancing cancer treatment: A review of immune checkpoint inhibitors and combination strategies","volume":"17","author":"Mc Neil","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00530","article-title":"Immune-related adverse events: A case-based approach","volume":"9","author":"Connolly","year":"2019","journal-title":"Front Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"103700","DOI":"10.1016\/j.critrevonc.2022.103700","article-title":"The efficacy of immune checkpoint inhibitors in rare tumors: A systematic review of published clinical trials","volume":"174","author":"Guven","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"104808","DOI":"10.1016\/j.critrevonc.2025.104808","article-title":"T cell-mediated mechanisms of immune-related adverse events induced by immune checkpoint inhibitors","volume":"213","author":"Li","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1007\/s00520-025-09952-2","article-title":"Hematologic immune-related adverse effects of immune checkpoint inhibitors: a review","volume":"33","author":"Cruz Carreras","year":"2025","journal-title":"Support Care Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-13-1057","article-title":"Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention","volume":"23","author":"Karimi","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20230941","article-title":"Antigen-independent, autonomous B cell receptor signaling drives activated B cell DLBCL","volume":"221","author":"Eken","year":"2024","journal-title":"J Exp Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030835","article-title":"The immunology of DLBCL","volume":"15","author":"Takahara","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25010010","article-title":"B-cell receptor signaling and beyond: the role of ig\u03b1 (CD79a)\/ig\u03b2 (CD79b) in normal and Malignant B cells","volume":"25","author":"Tkachenko","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006784","article-title":"Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphoma","volume":"138","author":"Xu","year":"2021","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2023.04.002","article-title":"Immune mechanisms of toxicity from checkpoint inhibitors","volume":"9","author":"Wang","year":"2023","journal-title":"Trends Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1016\/j.immuni.2024.10.014","article-title":"Impaired development of memory B cells and antibody responses in humans and mice deficient in PD-1 signaling","volume":"57","author":"Ogishi","year":"2024","journal-title":"Immunity"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20232104","article-title":"Anti-PD-1 therapy triggers Tfh cell-dependent IL-4 release to boost CD8 T cell responses in tumor-draining lymph nodes","volume":"221","author":"Ruggiu","year":"2024","journal-title":"J Exp Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008636","article-title":"B cells and the coordination of immune checkpoint inhibitor response in patients with solid tumors","volume":"12","author":"Flippot","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1877","article-title":"PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells","volume":"11","author":"Good-Jacobson","year":"2010","journal-title":"Nat Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.immuni.2018.06.012","article-title":"PD-1 controls follicular T helper cell positioning and function","volume":"49","author":"Shi","year":"2018","journal-title":"Immunity"},{"key":"B21","doi-asserted-by":"publisher","first-page":"108111","DOI":"10.1016\/j.pharmthera.2022.108111","article-title":"The immune modifying effects of chemotherapy and advances in chemo-immunotherapy","volume":"236","author":"Principe","year":"2022","journal-title":"Pharmacol Ther"},{"key":"B22","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.it.2025.03.007","article-title":"Epstein-Barr virus-mediated immune evasion in tumor promotion","volume":"46","author":"Yuan","year":"2025","journal-title":"Trends Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e70139","DOI":"10.1096\/fj.202301980RR","article-title":"The novel immune landscape of immune-checkpoint blockade in EBV-associated Malignancies","volume":"38","author":"Zhang","year":"2024","journal-title":"FASEB J"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1763711\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:27:24Z","timestamp":1771928844000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1763711\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":23,"alternative-id":["10.3389\/fimmu.2026.1763711"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1763711","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"article-number":"1763711"}}